This model has an amplification of IGFR. Based on published data [24], amplification of IGFR would render the tumor resistant to the effects of AZD8186 (both in terms of efficacy and AKT modulation), but retain sensitivity to capivasertib. The gene discussed is IGF1R; the disease is neoplasm.